Faeth Therapeutics, Inc. (FTH)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $19.20
- As of
Kresmion compiles this page from FTH's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Faeth Therapeutics, Inc. (FTH): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-27.
See the full FTH dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for FTH on one page. Preview it with sample data, then open it live with a free account.
Preview the FTH dossierActive events for FTH
- mediumEarnings above estimates
Q2-2026: Beat consensus by 7.7%, EPS $-2.84 vs $-3.0784 estimate
FREE, NO ACCOUNT
Every event on FTH, as it fires
New filings, 13F moves and cross asset events on FTH land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in FTH (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 81728A207 · 2026Q2 | $510K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 81728A207 · 2026Q2 | $307K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, FTH
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
FTH against its peers
FTH's return on equity of -113.4% ranks in the 7th percentile of 20 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | FTH | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 10.3M | n/a | 16 |
| Gross margin | n/a | 69.9% | n/a | 5 |
| Operating margin | n/a | -47.0% | n/a | 13 |
| Net margin | n/a | -66.0% | n/a | 13 |
| Return on equity | -113.4% | -48.7% | 7 | 20 |
Peers (21): CTMX, OCS, VALN, CBIO, ENTX, MNPR, NGNE, ARVN, DMAC, EPRX, MPLT, RGNX, STTK, MYGN, OLMA, PBYI, MDXG, IRWD, OVID, PRTA, ALLO. Left out: BLSM (no annual filing), DRUG (period gap), AGMB (no annual filing), ETRA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (FTH: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow FTH on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to FTH for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.